



TITLE OF INVENTION

ACELLULAR PERTUSSIS VACCINES AND METHODS
OF PREPARATION THEREOF

FIELD OF INVENTION

5 The present invention relates to acellular pertussis
vaccines, components thereof, and their preparation.

REFERENCE TO RELATED APPLICATION

 This application is a continuation-in-part of
compending United States patent application no. 08/433,646
10 filed May 4, 1995.

BACKGROUND TO THE INVENTION

 Whooping cough or pertussis is a severe, highly
contagious upper respiratory tract infection caused by
Bordetella pertussis. The World Health Organization
15 estimates that there are 60 million cases of pertussis
per year and 0.5 to 1 million associated deaths (ref. 1.
Throughout this specification, various references are
referred to in parenthesis to more fully describe the
state of the art to which this invention pertains. Full
20 bibliographic information for each citation is found at
the end of the specification, immediately following the
claims. The disclosures of these references are hereby
incorporated by reference into the present disclosure).
In unvaccinated populations, a pertussis incidence rate
25 as high as 80% has been observed in children under 5
years old (ref. 2). Although pertussis is generally
considered to be a childhood disease, there is increasing
evidence of clinical and asymptomatic disease in
adolescents and adults (refs. 3, 4 and 5).

30 The introduction of whole-cell vaccines composed of
chemically- and heat-inactivated B. pertussis organisms
in the 1940's was responsible for a dramatic reduction in
the incidence of whooping cough caused by B. pertussis.
The efficacy rates for whole-cell vaccines have been

estimated at up to 95% depending on case definition (ref. 6). While infection with B. pertussis confers life-long immunity, there is increasing evidence for waning protection after immunization with whole-cell vaccines (ref. 3). Several reports citing a relationship between whole-cell pertussis vaccination, reactogenicity and serious side-effects led to a decline in vaccine acceptance and consequent renewed epidemics (ref. 7). More recently defined component pertussis vaccines have been developed.

Antigens for Defined Pertussis Vaccines

Various acellular pertussis vaccines have been developed and include the Bordetella pertussis antigens, Pertussis Toxin (PT), Filamentous haemagglutinin (FHA), the 69kDa outer membrane protein (pertactin) and fimbrial agglutinogens (see Table 1 below. The Tables appear at the end of the specification).

Pertussis Toxin

Pertussis toxin is an exotoxin which is a member of the A/B family of bacterial toxins with ADP-ribosyltransferase activity (ref. 8). The A-moiety of these toxins exhibit the ADP-ribosyltransferase activity and the B portion mediates binding of the toxin to host cell receptors and the translocation of A to its site of action. PT also facilitates the adherence of B. pertussis to ciliated epithelial cells (ref. 9) and also plays a role in the invasion of macrophages by B. pertussis (ref. 10).

All acellular pertussis vaccines have included PT, which has been proposed as a major virulence factor and protective antigen (ref. 11, 12). Natural infection with B. pertussis generates both humoral and cell-mediated responses to PT (refs. 13 to 17). Infants have transplacentally-derived anti-PT antibodies (refs. 16, 18) and human colostrum containing anti-PT antibodies was effective in the passive protection of mice against

aerosol infection (ref. 19). A cell-mediated immune (CMI) response to PT subunits has been demonstrated after immunization with an acellular vaccine (ref. 20) and a CMI response to PT was generated after whole-cell vaccination (ref. 13). Chemically-inactivated PT in whole-cell or component vaccines is protective in animal models and in humans (ref. 21). Furthermore, monoclonal antibodies specific for subunit S1 protect against B. pertussis infection (refs. 22 and 23).

10 The main pathophysiological effects of PT are due to its ADP-ribosyltransferase activity. PT catalyses the transfer of ADP-ribose from NAD to the G_i guanine nucleotide-binding protein, thus disrupting the cellular adenylate cyclase regulatory system (ref. 24). PT also
15 prevents the migration of macrophages and lymphocytes to sites of inflammation and interferes with the neutrophil-mediated phagocytosis and killing of bacteria (ref. 25). A number of in vitro and in vivo assays have been used to assess the enzymatic activity of S1 and/or PT, including
20 the ADP-ribosylation of bovine transducin (ref. 26), the Chinese hamster ovary (CHO) cell clustering assay (ref. 27), histamine sensitization (ref. 28), leukocytosis, and NAD glycohydrolase. When exposed to PT, CHO cells develop a characteristic clustered morphology. This
25 phenomenon is dependent upon the binding of PT, and subsequent translocation and ADP-ribosyltransferase activity of S1 and thus the CHO cell clustering assay is widely used to test the integrity and toxicity of PT holotoxins.

30 Filamentous Haemagglutinin

Filamentous haemagglutinin is a large (220 kDa) non-toxic polypeptide which mediates attachment of B. pertussis to ciliated cells of the upper respiratory tract during bacterial colonization (refs. 9, 29).
35 Natural infection induces anti-FHA antibodies and cell mediated immunity (refs. 13, 15, 17, 30 and 31). Anti-

FHA antibodies are found in human colostrum and are also transmitted transplacentally (refs. 17, 18 and 19). Vaccination with whole-cell or acellular pertussis vaccines generates anti-FHA antibodies and acellular vaccines containing FHA also induce a CMI response to FHA (refs. 20, 32). FHA is a protective antigen in a mouse respiratory challenge model after active or passive immunization (refs. 33, 34). However, alone FHA does not protect in the mouse intracerebral challenge potency assay (ref. 28).

69 kDa Outer Membrane Protein (Pertactin)

The 69kDa protein is an outer membrane protein which was originally identified from B. bronchiseptica (ref. 35). It was shown to be a protective antigen against B. bronchiseptica and was subsequently identified in both B. pertussis and B. parapertussis. The 69kDa protein binds directly to eukaryotic cells (ref. 36) and natural infection with B. pertussis induces an anti-P.69 humoral response (ref. 14) and P.69 also induces a cell-mediated immune response (ref. 17, 37, 38). Vaccination with whole-cell or acellular vaccines induces anti-P.69 antibodies (refs. 32, 39) and acellular vaccines induce P.69 CMI (ref. 39). Pertactin protects mice against aerosol challenge with B. pertussis (ref. 40) and in combination with FHA, protects in the intracerebral challenge test against B. pertussis (ref. 41). Passive transfer of polyclonal or monoclonal anti-P.69 antibodies also protects mice against aerosol challenge (ref. 42).

Agglutinogens

Serotypes of B. pertussis are defined by their agglutinating fimbriae. The WHO recommends that whole-cell vaccines include types 1, 2 and 3 agglutinogens (Aggs) since they are not cross-protective (ref. 43). Agg 1 is non-fimbrial and is found on all B. pertussis strains while the serotype 2 and 3 Aggs are fimbrial. Natural infection or immunization with whole-cell or

acellular vaccines induces anti-Agg antibodies (refs. 15, 32). A specific cell-mediated immune response can be generated in mice by Agg 2 and Agg 3 after aerosol infection (ref. 17). Aggs 2 and 3 are protective in mice against respiratory challenge and human colostrum containing anti-agglutinogens will also protect in this assay (refs. 19, 44, 45).

Acellular Vaccines

The first acellular vaccine developed was the two-component PT + FHA vaccine (JN1H 6) of Sato et al. (ref. 46). This vaccine was prepared by co-purification of PT and FHA antigens from the culture supernatant of B. pertussis strain Tohama, followed by formalin toxoiding. Acellular vaccines from various manufacturers and of various compositions have been used successfully to immunize Japanese children against whooping cough since 1981 resulting in a dramatic decrease in incidence of disease (ref. 47). The JN1H 6 vaccine and a mono-component PT toxoid vaccine (JN1H 7) were tested in a large clinical trial in Sweden in 1986. Initial results indicated lower efficacy than the reported efficacy of a whole-cell vaccine, but follow-up studies have shown it to be more effective against milder disease diagnosed by serological methods (refs. 48, 49, 50, 51). However, there was evidence for reversion to toxicity of formalin-inactivated PT in these vaccines. These vaccines were also found to protect against disease rather than infection.

A number of new acellular pertussis vaccines are currently being assessed which include combinations of PT, FHA, P.69, and/or agglutinogens and these are listed in Table 1. Several techniques of chemical detoxication have been used for PT including inactivation with formalin (ref. 46), glutaraldehyde (ref. 52), hydrogen peroxide (ref. 53), and tetranitromethane (ref. 54).

Thus, current commercially-available acellular pertussis vaccines may not contain appropriate formulations of appropriate antigens in appropriate immunogenic forms to achieve a desired level of efficacy
5 in a pertussis-susceptible human population.

It would be desirable to provide efficacious acellular pertussis vaccines containing selected relative amounts of selected antigens and methods of production thereof.

10 SUMMARY OF THE INVENTION

The present invention is directed towards acellular pertussis vaccine preparations, components thereof, methods of preparation of such vaccines and their components, and methods of use thereof.

15 In accordance with one aspect of the invention there is provided a process for preparing an agglutinin preparation from a Bordetella strain, comprising the steps of:

(a) providing a cell paste of the Bordetella
20 strain;

(b) selectively extracting fimbrial agglutinogens from the cell paste to produce a first supernatant containing the agglutinogens and a first residual precipitate;

25 (c) separating the first supernatant from the first residual precipitate;

(d) incubating the first supernatant at a temperature and for a time to produce a clarified supernatant containing fimbrial agglutinogens and a
30 second precipitate containing non-agglutinin contaminants;

(e) concentrating the clarified supernatant to produce a crude fimbrial agglutinin containing solution; and

35 (f) purifying agglutinogens from the crude fimbriae solution to produce the agglutinin preparation.

The Bordetella strain may be B. pertussis. The first supernatant may be incubated at a temperature of about 50°C to about 100°C, including about 75°C to about 85°C, preferably about 80°C. The time of incubation may be about 10 minutes to about 60 minutes, preferably about 30 minutes. The fimbrial agglutinogens may be selectively extracted from the cell paste by dispersing the cell paste in a buffer comprising about 1M to about 6M urea. In a particular embodiment, the first supernatant is concentrated before incubating at the time and temperature to produce the clarified supernatant.

The clarified supernatant may be concentrated by any convenient means including precipitating fimbrial agglutinogens from the clarified supernatant, separating the precipitated fimbrial agglutinogens from the resulting supernatant, and solubilizing the precipitated fimbrial agglutinogens. The precipitation may be effected by the addition of a polyethylene glycol, such as a polyethylene glycol of molecular weight of about 8000, to the clarified supernatant. The concentration of polyethylene glycol employed in such precipitation may be about 3% to about 5%, preferably about 4.3 to about 4.7%, to effect precipitation of said fimbrial agglutinogens from the clarified supernatant.

The fimbrial agglutinogens may be purified from the crude fimbriae solution by column chromatography and the column chromatography may include gel filtration, such as by the use of Sephadex 6B and/or PEI silica column chromatography. In a particular aspect of the invention, the agglutinogens are provided as a sterile agglutinin preparation sterilized by, for example, sterile-filtration of the run-through from the column chromatography purification. In a particular embodiment, the sterile fimbrial agglutinin preparation is adsorbed onto a mineral salt adjuvant, which may be alum.

In a particular aspect of the invention, there is provided a fimbrial agglutinin preparation from a Bordetella strain comprising fimbrial agglutinin 2 (Agg 2) and fimbrial agglutinin 3 (Agg 3) substantially free from agglutinin 1. Since agglutinin 1 is reported to be the lipooligosaccharide (LOS) of B. pertussis which is reactogenic, the provision of a fimbrial agglutinin substantially free of LOS, therefore, reduces the reactogenicity due thereto. The weight ratio of Agg 2 to Agg 3 may be from about 1.5:1 to about 2:1 in such fimbrial agglutinin preparation. In a particular embodiment of the present invention, there is provided a fimbrial agglutinin preparation prepared by the method as provided herein.

In a further aspect of the invention, there is provided an immunogenic composition comprising the fimbrial agglutinin preparation as provided herein. The immunogenic composition may be formulated as a vaccine for in vivo use for protecting a host immunized therewith from disease caused by Bordetella and may comprise at least one other Bordetella antigen. The at least one other Bordetella antigen may be filamentous haemagglutinin, the 69 kDa outer membrane protein adenylate cyclase, Bordetella lipooligosaccharide, outer membrane proteins and pertussis toxin or a toxoid thereof, including genetically detoxified analogs thereof.

In a further aspect of the invention, the immunogenic composition as provided herein may comprise at least one non-Bordetella immunogen. Such non-Bordetella immunogen may be diphtheria toxoid, tetanus toxoid, capsular polysaccharide of Haemophilus, outer membrane protein of Haemophilus, hepatitis B surface antigen, polio, mumps, measles and/or rubella.

The immunogenic compositions as provided herein may further comprise an adjuvant and such adjuvant may be

aluminum phosphate, aluminum hydroxide, Quil A, QS21, calcium phosphate, calcium hydroxide, zinc hydroxide, a glycolipid analog, an octodecyl ester of an amino acid or a lipoprotein.

5 In accordance with a specific aspect of the present invention, there is provided a vaccine composition for protecting an at-risk human population against a case of disease caused by infection by B. pertussis, which comprises pertussis toxoid, filamentous haemagglutinin,
10 pertactin and agglutinogens in purified form in selected relative amounts to confer protection to the extent of at least about 70% of members of the at-risk population.

 Such vaccine composition may contain about 5 to about 30 μg nitrogen of pertussis toxoid, about 5 to
15 about 30 μg nitrogen of filamentous haemagglutinin, about 3 to about 15 μg nitrogen of pertactin and about 1 to about 10 μg nitrogen of agglutinogens.

 In one specific embodiment, the vaccine may comprise pertussis toxoid, filamentous haemagglutinin, the 69 kDa
20 protein and filamentous agglutinogens of Bordetella at a weight ratio of about 10:5:5:3 as provided by about 10 μg of pertussis toxoid, about 5 μg of filamentous haemagglutinin, about 5 μg of 69 kDa protein and about 3 μg of fimbrial agglutinogens in a single human dose. In
25 a further particular embodiment, the vaccine may comprise pertussis toxoid, filamentous haemagglutinin, 69 kDa protein and fimbrial agglutinogens in a weight ratio of about 20:20:5:3 as provided by about 20 μg of pertussis toxoid, about 20 μg of filamentous haemagglutinin, about
30 5 μg of 69 kDa protein and about 3 μg of fimbrial agglutinogens in a single human dose. In a yet further particular embodiment, the vaccine may comprise pertussis toxoid filamentous haemagglutinin, 69 kDa protein and fimbrial agglutinogens in a weight ratio of about
35 20:10:10:6 as provided by about 20 μg of pertussis toxoid, about 10 μg of filamentous haemagglutinin, about

10 μ g of 69 kDa protein and about 6 μ g of fimbrial agglutinogens in a single human dose.

The extent of protection to the at-risk human population afforded by the vaccine composition of the invention may be at least about 80%, preferably about 85%, for a case of spasmodic cough of duration at least 21 days and culture-confirmed bacterial infection. The extent of protection to the at-risk human population may be at least about 70% for a case of mild pertussis having a cough of at least one day duration.

The agglutinogens component of the vaccine preferably comprise fimbrial agglutininogen 2 (Agg 2) and fimbrial agglutininogen 3 (Agg 3) substantially free from agglutininogen 1. The weight ratio of Agg 2 to Agg 3 may be from about 1.5:1 to about 2:1.

The vaccine provided herein may be combined with tetanus toxoid and diphtheria toxoid to provide a DTP vaccine. In one embodiment, the vaccine contains about 15 Lfs of diphtheria toxoid and about 5 Lfs of tetanus toxoid.

In addition, the vaccine may also comprise an adjuvant, particularly alum.

In such particular embodiments, the immunogenic compositions provide for an immune response profile to each of the antigens contained therein and the response profile is substantially equivalent to that produced by a whole cell pertussis vaccine.

In a further aspect of the invention, there is provided a method of immunizing a host against disease caused by Bordetella, comprising administering to the host, which may be human, an immunoeffective amount of the immunogenic composition or vaccine as provided herein.

In a further aspect of the present invention, there is provided a method of immunizing an at-risk human population against disease caused by infection by B.

pertussis, which comprises administering to members of the at-risk human population an immunoeffective amount of the vaccine composition provided herein to confer protection to the extent of at least about 70% of the members of the at-risk population.

Advantages of the present invention include a simple process for the preparation of immunogenic agglutinin preparations suitable for inclusion in acellular pertussis vaccines to increase the efficacy of such vaccines.

Agglutinin preparations provided by the present invention have utility in the formulation of acellular multi-component vaccines for protecting a host immunized therewith from disease caused by Bordetella including B. pertussis. In particular, the immunogenic compositions containing agglutinin preparations as provided herein have been selected by the National Institute of Allergy and Infectious Diseases (NIAID) of the United States Government for evaluation in a double-blind, human efficacy clinical trial, thereby establishing a sufficient basis to those especially skilled in the art that the compositions will be effective to some degree in preventing the stated disease (pertussis). This trial is ongoing as of the date of filing of this U.S. patent application. The subject of that trial (being a vaccine as provided herein) has met the burden of being reasonably predictive of utility.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further understood from the following detailed description and Examples with reference to the accompanying drawing in which:

Figure 1 is a schematic flow sheet of a procedure for the isolation of an agglutinin preparation from a Bordetella strain in accordance with one aspect of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

In one aspect, the present invention provides novel techniques which can be employed for preparing agglutinin preparations from a Bordetella strain.

5 Referring to Figure 1, there is illustrated a flow sheet of a method for preparing an agglutinin preparation from a Bordetella strain. As seen in Figure 1, a Bordetella cell paste containing the agglutinogens, such as B. pertussis cell paste, is extracted with, for example, a urea-containing buffer, such as 10 mM
10 potassium phosphate, 150 mM NaCl and 4M urea, to selectively extract the agglutinogens from the cell paste to produce a first supernatant (sp1) containing agglutinogens and a first residual precipitate (ppt1).

15 The first supernatant (sp1) is separated from the first residual precipitate (ppt1) such as by centrifugation. The residual precipitate (ppt1) is discarded. The clarified supernatant (sp1) then may be concentrated and diafiltered against, for example, 10mM potassium
20 phosphate/150mM NaCl/0.1% Triton X-100 using, for example, a 100 to 300 kDa NMWL membrane filter.

The first supernatant then is incubated at a temperature and for a time to produce a clarified supernatant (sp2) containing agglutinogens and a second
25 discard precipitate (ppt2) containing non-agglutinin contaminants. Appropriate temperatures include about 50°C to about 100°C, including about 75° to about 85°C, and appropriate incubation times include about 1 to about 60 minutes. The clarified supernatant then is
30 concentrated by, for example, the addition of polyethylene glycol of molecular weight about 8000 (PEG 8000) to a final concentration of about $4.5 \pm 0.2\%$ and stirring gently for a minimum of about 30 minutes to produce a third precipitate (ppt3) which may be collected
35 by centrifugation. The remaining supernatant sp3 is discarded.

This third precipitate (ppt3) is extracted with, for example, a buffer comprising 10mM potassium phosphate/150 mM NaCl to provide the crude fimbrial agglutinin-containing solution. 1M potassium phosphate may be added
5 to the crude fimbrial solution to make it about 100mM with respect to potassium phosphate. Alternatively, the clarified supernatant of heat-treated fimbrial agglutinogens can be purified without precipitation by gel-filtration chromatography using a gel, such as
10 Sepharose CL6B. The fimbrial agglutinogens in the crude solution then are purified by column chromatography, such as, by passing through a PEI silica column, to produce the fimbrial agglutinin preparation in the run-through.

This fimbrial agglutinin containing run-through
15 may be further concentrated and diafiltered against, for example, a buffer containing 10mM potassium phosphate/150mM NaCl using a 100-300 kDa NMWL membrane. The agglutinin preparation may be sterilized by filtration through a $\leq 0.22 \mu\text{M}$ membrane filter, to
20 provide the final purified fimbrial agglutinin preparation containing fimbrial agglutinin 2 and 3.

The present invention extends to an agglutinin preparation from a Bordetella strain comprising fimbrial agglutinin 2 (Agg 2) and fimbrial agglutinin 3 (Agg
25 3) substantially free from agglutinin 1. The weight ratio of Agg 2 to Agg 3 may be from about 1.5:1 to about 2:1. Such fimbrial agglutinin preparations may be produced by the method as provided herein and described in detail above. The present invention also extends to
30 immunogenic compositions (including vaccines) comprising the fimbrial agglutinin preparations as provided herein. Such vaccines may contain other Bordetella immunogens including filamentous haemagglutinin, the 69 kDa outer membrane protein and pertussis toxin or a
35 toxoid thereof, including genetically detoxified analogs of PT as described in, for example, ref. 68 and non-

Bordetella immunogens including diphtheria toxoid, tetanus toxoid, capsular polysaccharide of Haemophilus, outer membrane protein of Haemophilus, hepatitis B surface antigen, polio, mumps, measles and rubella. Each
 5 of the Bordetella antigens is individually absorbed to adjuvant (such as alum) to provide for convenient and rapid production of vaccines containing selected relative amounts of antigens in vaccines as provided herein.

In selected embodiments, the invention provides
 10 vaccines with the following characteristics (μ g proteins used herein are based on Kjeldahl test results performed on purified concentrates and are expressed as μ g of protein nitrogen), all of which may be administered by intramuscular injection:

15 (a) CP_{10/5/5/3}DT

One formulation of component pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{10/5/5/3}DT. Each 0.5 ml human dose of CP_{10/5/5/3}DT was formulated to contain about:

20	10 μ g	Pertussis toxoid (PT)
	5 μ g	Filamentous haemagglutinin (FHA)
	5 μ g	Fimbrial agglutinogens 2 and 3 (FIMB)
	3 μ g	69 kDa outer membrane protein
	15 Lf	Diphtheria toxoid
25	5 Lf	Tetanus toxoid
	1.5 mg	Aluminum phosphate
	0.6%	2-phenoxyethanol, as preservative

(b) CP_{20/20/5/3}DT

Another formulation of component pertussis vaccine
 30 combined with diphtheria and tetanus toxoids was termed CP_{20/20/5/3}DT. Each 0.5 ml human dose of CP_{20/20/5/3}DT was formulated to contain about:

	20 μ g	Pertussis toxoid (PT)
	20 μ g	Filamentous haemagglutinin (FHA)
35	5 μ g	Fimbrial agglutinogens 2 and 3 (FIMB)
	3 μ g	69 kDa outer membrane protein
	15 Lf	Diphtheria toxoid
	5 Lf	Tetanus toxoid

1.5 mg Aluminum phosphate
 0.6% 2-phenoxyethanol, as preservative

(c) CP_{10/5/5}DT

One formulation of component pertussis vaccine
 5 combined with diphtheria and tetanus toxoids was termed
 CP_{10/5/5}DT. Each 0.5 mL human dose of CP_{10/5/5} was formulated
 to contain about:

10 10 µg Pertussis toxoid (PT)
 5 µg Filamentous haemagglutinin (FHA)
 10 5 µg Fimbrial agglutinogens 2 and 3 (FIMB)

 15 Lf Diphtheria toxoid
 5 Lf Tetanus toxoid

1.5 mg Aluminum phosphate
 0.6% 2-phenoxyethanol as preservative

15 (d) CP_{20/10/10/6}DT

A further formulation of component pertussis vaccine
 combined with diphtheria and tetanus toxoids was termed
 CP_{20/10/10/6}DT. Each 0.5 ml human dose of CP_{20/10/10/6}DT was
 formulated to contain about:

20 20 µg Pertussis toxoid (PT)
 10 µg Filamentous haemagglutinin (FHA)
 10 µg Fimbrial agglutinogens 2 and 3 (FIMB)
 6 µg 69 kDa outer membrane protein (69kDA)

 25 15 Lf Diphtheria toxoid
 5 Lf Tetanus toxoid

1.5 mg Aluminum phosphate
 0.6% 2-phenoxyethanol, as preservative

The other Bordetella immunogens, pertussis toxin
 (including genetically detoxified analogs thereof, as
 30 described in, for example, Klein et al, U.S. Patent No.
 5,085,862 assigned to the assignee hereof and
 incorporated herein by reference thereto), FHA and the 69
 kDa protein may be produced by a variety of methods such
 as described below:

Purification of PT

PT may be isolated from the culture supernatant of a B. pertussis strain using conventional methods. For example, the method of Sekura et al (ref. 55) may be used. PT is isolated by first absorbing culture supernatant onto a column containing the dye-ligand gel matrix, Affi-Gel Blue (Bio-Rad Laboratories, Richmond, CA). PT is eluted from this column by high salt, such as, 0.75 M magnesium chloride and, after removing the salt, is passed through a column of fetuin-Sepharose affinity matrix composed of fetuin linked to cyanogen bromide-activated Sepharose. PT is eluted from the fetuin column using 4M magnesium salt.

Alternatively, the method of Irons et al (ref. 56) may be used. Culture supernatant is absorbed onto a CNBr-activated Sepharose 4B column to which haptoglobin is first covalently bound. The PT binds to the absorbent at pH 6.5 and is eluted from the column using 0.1M Tris/0.5M NaCl buffer by a stepwise change to pH 10.

Alternatively, the method described in U.S. Patent No. 4,705,686 granted to Scott et al on November 10, 1987 and incorporated herein by reference thereto may be used. In this method culture supernatants or cellular extracts of B. pertussis are passed through a column of an anion exchange resin of sufficient capacity to adsorb endotoxin but permit Bordetella antigens to flow through or otherwise be separated from the endotoxin.

Alternatively, PT may be purified by using perlite chromatography, as described in EP Patent No. 336 736, assigned to the assignee thereof and incorporated herein by reference thereto.

Detoxification of PT

PT is detoxified to remove undesired activities which could cause side reactions of the final vaccine. Any of a variety of conventional chemical detoxification

methods can be used, such as treatment with formaldehyde, hydrogen peroxide, tetranitro-methane, or glutaraldehyde.

For example, PT can be detoxified with glutaraldehyde using a modification of the procedure described in Munoz et al (ref. 57). In this detoxification process purified PT is incubated in a solution containing 0.01 M phosphate buffered saline. The solution is made 0.05% with glutaraldehyde and the mixture is incubated at room temperature for two hours, and then made 0.02 M with L-lysine. The mixture is further incubated for two hours at room temperature and then dialyzed for two days against 0.01 M PBS. In a particular embodiment, the detoxification process of EP Patent No. 336 736 may be used. Briefly PT may be detoxified with glutaraldehyde as follows:

Purified PT in 75mM potassium phosphate at pH 8.0 containing 0.22M sodium chloride is diluted with an equal volume of glycerol to protein concentrations of approximately 50 to 400 $\mu\text{g/ml}$. The solution is heated to 37°C and detoxified by the addition of glutaraldehyde to a final concentration of 0.5% (w/v). The mixture is kept at 37°C for 4 hrs and then aspartic acid (1.5 M) is added to a final concentration of 0.25 M. The mixture is incubated at room temperature for 1 hour and then diafiltered with 10 volumes of 10 mM potassium phosphate at pH 8.0 containing 0.15M sodium chloride and 5% glycerol to reduce the glycerol and to remove the glutaraldehyde. The PT toxoid is sterile-filtered through a 0.2 μM membrane.

If recombinant techniques are used to prepare a PT mutant molecule which shows no or little toxicity, for use as the toxoided molecule, chemical detoxification is not necessary.

Purification of FHA

FHA may be purified from the culture supernatant essentially as described by Cowell et al (ref. 58).

Growth promoters, such as methylated beta-cyclodextrins, may be used to increase the yield of FHA in culture supernatants. The culture supernatant is applied to a hydroxylapatite column. FHA is adsorbed onto the column, but PT is not. The column is extensively washed with Triton X-100 to remove endotoxin. FHA is then eluted using 0.5M NaCl in 0.1M sodium phosphate and, if needed, passed through a fetuin-Sepharose column to remove residual PT. Additional purification can involve passage though a Sepharose CL-6B column.

Alternatively, FHA may be purified using monoclonal antibodies to the antigen, where the antibodies are affixed to a CNBr-activated affinity column (ref. 59).

Alternatively, FHA may be purified by using perlite chromatography as described in the above-mentioned EP 336 736.

Purification of 69 kDa Outer Membrane Protein (pertactin)

The 69 kDa outer membrane protein (69K or pertactin) may be recovered from bacterial cells by first inactivating the cells with a bacteriostatic agent, such as thimerosal, as described in published EP 484 621 and incorporated herein by reference thereto. The inactivated cells are suspended in an aqueous medium, such as PBS (pH 7 to 8) and subjected to repeated extraction at elevated temperature (45 to 60°C) with subsequent cooling to room temperature or 4°C. The extractions release the 69K protein from the cells. The material containing the 69K protein is collected by precipitation and passed through an Affi-gel Blue column. The 69K protein is eluted with a high concentration of salt, such as 0.5M magnesium chloride. After dialysis, it is passed through a chromatofocusing support.

Alternatively, the 69 kDa protein may be purified from the culture supernatant of a B. pertussis culture, as described in published PCT Application WO 91/15505, in

the name of the assignee hereof and incorporated herein by reference thereto.

Other appropriate methods of purification of the 69 kDa outer membrane protein from B. pertussis are described in U.S. Patent No. 5,276,142, granted to Gotto et al on January 4, 1984 and in U.S. Patent No. 5,101,014, granted to Burns on March 31, 1992.

A number of clinical trials were performed in humans as described herein to establish the safety, non-reactogenicity and utility of component vaccines containing fimbrial agglutinogens prepared as described herein, for protection against pertussis. In particular, immune responses to each of the antigens contained in the vaccines (as shown, for example, in Table 3 below) were obtained. One particular acellular pertussis vaccine CP_{10/5/5/3}DT was analyzed in a large placebo-controlled, multi-centre, double-randomized clinical trial in an at-risk human population to estimate the efficacy of the vaccine against typical pertussis.

The case definition for typical pertussis disease was:

Twenty-one days or more of spasmodic cough, and either culture-confirmed B. pertussis,
or
 serological evidence of Bordetella specific infection indicated by a 100% IgG or IgA antibody rise in ELISA against FHA or PT in paired sera,
or
 if serological data is lacking, the study child has been in contact with a case of culture-confirmed B. pertussis in the household with onset of cough within 28 days before or after the onset of cough in the study child.

The results of this study showed CP_{10/5/5/3}DT to be about 85% efficacious in preventing pertussis as defined in the case definition for typical pertussis disease as described above. In the same study, a two-component pertussis acellular vaccine containing only PT and FHA was about 58% efficacious and a whole-cell pertussis

vaccine was about 48% efficacious (see Table 4 below). In addition, the CP_{10/5/5/3}DT vaccine prevented mild pertussis defined as a cough of at least one day duration to an efficacy of about 77%. In particular, the profile
5 of immune response obtained was substantially the same as that obtained following immunization with whole-cell pertussis vaccines which are reported to be highly efficacious against pertussis.

Vaccine Preparation and Use

10 Thus, immunogenic compositions, suitable to be used as vaccines, may be prepared from the Bordetella immunogens as disclosed herein. The vaccine elicits an immune response in a subject which produces antibodies that may be opsonizing or bactericidal. Should the
15 vaccinated subject be challenged by B. pertussis, such antibodies bind to and inactivate the bacteria. Furthermore, opsonizing or bactericidal antibodies may also provide protection by alternative mechanisms.

Immunogenic compositions including vaccines may be
20 prepared as injectibles, as liquid solutions or emulsions. The Bordetella immunogens may be mixed with pharmaceutically acceptable excipients which are compatible with the immunogens. Such excipients may include water, saline, dextrose, glycerol, ethanol, and
25 combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be
30 administered parenterally, by injection subcutaneously or intramuscularly. The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, immunogenic and protective.
35 The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the

immune system of the individual to synthesize antibodies, and, if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of micrograms of the immunogens. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host.

The concentration of the immunogens in an immunogenic composition according to the invention is in general about 1 to about 95%. A vaccine which contains antigenic material of only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

Immunogenicity can be significantly improved if the antigens are co-administered with adjuvants, commonly used as 0.005 to 0.5 percent solution in phosphate buffered saline. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.

Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to,

for example, vaccines. Intrinsic adjuvants, such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are typically non-covalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have been identified that enhance the immune response to antigens delivered parenterally. Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in increasing antibody responses to diphtheria and tetanus toxoids is well established and, more recently, a HBsAg vaccine has been adjuvanted with alum. While the usefulness of alum is well established for some applications, it has limitations. For example, alum is ineffective for influenza vaccination and inconsistently elicits a cell mediated immune response. The antibodies elicited by alum-adjuvanted antigens are mainly of the IgG1 isotype in the mouse, which may not be optimal for protection by some vaccinal agents.

A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

To efficiently induce humoral immune responses (HIR) and cell-mediated immunity (CMI), immunogens are often emulsified in adjuvants. Many adjuvants are toxic, inducing granulomas, acute and chronic inflammations

(Freund's complete adjuvant, FCA), cytolysis (saponins and Pluronic polymers) and pyrogenicity, arthritis and anterior uveitis (LPS and MDP). Although FCA is an excellent adjuvant and widely used in research, it is not
5 licensed for use in human or veterinary vaccines because of its toxicity.

Desirable characteristics of ideal adjuvants include:

- (1) lack of toxicity;
- 10 (2) ability to stimulate a long-lasting immune response;
- (3) simplicity of manufacture and stability in long-term storage;
- (4) ability to elicit both CMI and HIR to antigens
15 administered by various routes;
- (5) synergy with other adjuvants;
- (6) capability of selectively interacting with populations of antigen presenting cells (APC):
- (7) ability to specifically elicit appropriate T_H1
20 or T_H2 cell-specific immune responses; and
- (8) ability to selectively increase appropriate antibody isotype levels (for example, IgA) against antigens.

U.S. Patent No. 4,855,283 granted to Lockhoff et al
25 on August 8, 1989 which is incorporated herein by reference thereto teaches glycolipid analogues including N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immuno-modulators or
30 adjuvants. Thus, Lockhoff et al. (U.S. Patent No. 4,855,283 and ref. 60) reported that N-glycolipid analogs displaying structural similarities to the naturally-occurring glycolipids, such as glycosphingolipids and glycoglycerolipids, are capable of eliciting strong
35 immune responses in both herpes simplex virus vaccine and pseudorabies virus vaccine. Some glycolipids have been

Example 2:

This Example describes the purification of antigens from the Bordetella pertussis cell culture.

Production of Broth and Cell Concentrates:

5 Bacterial suspension was grown in two production fermenters, at 34°C to 37°C for 35 to 50 hours. The fermenters were sampled for media sterility testing. The suspension was fed to a continuous-flow disk-stack centrifuge (12,000 x g) to separate cells from the broth.
10 Cells were collected to await extraction of fimbriae component. The clarified liquor was passed through $\leq 0.22 \mu\text{m}$ membrane filter. The filtered liquor was concentrated by ultra filtration using a 10 to 30 kDa nominal molecular weight limit (NMWL) membrane. The
15 concentrate was stored to await separation and purification of the Pertussis Toxin (PT), Filamentous haemagglutinin (FHA) and 69 kDa (pertactin) components.

Separation of the Broth Components:

The broth components (69 kDa, PT and FHA) were
20 separated and purified by perlite chromatography and selective elution steps, essentially as described in EP Patent No. 336 736 and applicants published PCT Application No. WO 91/15505, described above. The specific purification operations effected are described
25 below.

Pertussis Toxin (PT):

The perlite column was washed with 50 mM Tris, 50 mM Tris/0.5% Triton X-100 and 50 mM Tris buffers. The PT fraction was eluted from the perlite column with 50 mM
30 Tris/0.12M NaCl buffer.

The PT fraction from the perlite chromatography was loaded onto a hydroxylapatite column and then washed with 30mM potassium phosphate buffer. PT was eluted with 75mM potassium phosphate/225 mM NaCl buffer. The column was
35 washed with 200 mM potassium phosphate/0.6M NaCl to obtain the FHA fraction which was discarded. Glycerol

was added to the purified PT to 50% and the mixture was stored at 2°C to 8°C until detoxification, within one week.

Filamentous Haemagglutinin (FHA):

5 The FHA fraction was eluted from the perlite column with 50mM Tris/0.6M NaCl. Filamentous haemagglutinin was purified by chromatography over hydroxylapatite. The FHA fraction from the perlite column was loaded onto a hydroxylapatite column then washed with 30 mM potassium
10 phosphate containing 0.5% Triton X-100, followed by 30 mM potassium phosphate buffer. The PT fraction was eluted with 85 mM potassium phosphate buffer and discarded. The FHA fraction was then eluted with 200 mM potassium phosphate/0.6M NaCl and stored at 2°C to 8°C until
15 detoxification within one week.

69 kDa (pertactin):

 The broth concentrate was diluted with water for injection (WFI) to achieve a conductivity of 3 to 4 mS/cm and loaded onto a perlite column at a loading of 0.5 to
20 3.5 mg protein per ml perlite. The run-through (69 kDa Component Fraction) was concentrated by ultrafiltration using a 10 to 30 kDa NMWL membrane. Ammonium sulphate was added to the run-through concentrate to 35% \pm 3% (w/v) and the resulting mixture stored at 2°C to 8°C for
25 4 \pm 2 days or centrifuged (7,000 x g) immediately. Excess supernatant was decanted and the precipitate collected by centrifugation (7,000 x g). The 69 kDa pellet was either stored frozen at -20°C to -30°C or dissolved in Tris or phosphate buffer and used
30 immediately.

 The 69 kDa outer membrane protein obtained by the 35% (w/v) ammonium sulphate precipitation of concentrated perlite run-through was used for the purification. Ammonium sulphate (100 \pm 5 g per litre) was added to the
35 69 kDa fraction and the mixture stirred for at least 2 hours at 2°C to 8°C. The mixture was centrifuged (7,000

x g) to recover the supernatant. Ammonium sulphate (100 to 150 g per liter) was added to the supernatant and the mixture stirred for at least 2 hours at 2°C to 8°C. The mixture was centrifuged (7,000 x g) to recover the pellet, which was dissolved in 10 mM Tris, HCl, pH 8. The ionic strength of the solution was adjusted to the equivalent of 10 mM Tris HCl (pH 8), containing 15 mM ammonium sulphate.

The 69 kDa protein was applied to a hydroxylapatite column connected in tandem with a Q-Sepharose column. The 69 kDa protein was collected in the run-through, was flushed from the columns with 10 mM Tris, HCl (pH 8), containing 15 mM ammonium sulphate and pooled with 69 kDa protein in the run-through. The 69 kDa protein pool was diafiltered with 6 to 10 volumes of 10 mM potassium phosphate (pH 8), containing 0.15M NaCl on a 100 to 300 kDa NMWL membrane. The ultra filtrate was collected and the 69 kDa protein in the ultra filtrate concentrated.

The 69 kDa protein was solvent exchanged into 10 mM Tris HCl (pH8), and adsorbed onto Q-Sepharose, washed with 10 mM Tris HCl (pH 8)/5 mM ammonium sulphate. The 69 kDa protein was eluted with 50 mM potassium phosphate (pH 8). The 69 kDa protein was diafiltered with 6 to 10 volumes of 10 mM potassium phosphate (pH 8) containing 0.15M NaCl on a 10 to 30 kDa NMWL membrane. The 69 kDa protein was sterile filtered through a $\leq 0.22 \mu\text{m}$ filter. This sterile bulk was stored at 2°C to 8°C and adsorption was performed within three months.

Fimbrial Agglutinogens:

The agglutinogens were purified from the cell paste following separation from the broth. The cell paste was diluted to a 0.05 volume fraction of cells in a buffer containing 10 mM potassium phosphate, 150mM NaCl and 4M urea and was mixed for 30 minutes. The cell lysate was clarified by centrifugation (12,000 x g) then concentrated and diafiltered against 10mM potassium

phosphate/150mM NaCl/0.1% Triton X-100 using a 100 to 300 kDa NMWL membrane filter.

The concentrate was heat treated at 80°C for 30 min then reclarified by centrifugation (9,000 x g). PEG 8000
5 was added to the clarified supernatant to a final concentration of 4.5% \pm 0.2% and stirred gently for a minimum of 30 minutes. The resulting precipitate was collected by centrifugation (17,000 x g) and the pellet extracted with 10 mM potassium phosphate/150mM NaCl
10 buffer to provide a crude fimbrial agglutinin solution. The fimbrial agglutinogens were purified by passage over PEI silica. The crude solution was made 100 mM with respect to potassium phosphate using 1M potassium phosphate buffer and passed through the PEI silica
15 column.

The run-through from the columns was concentrated and diafiltered against 10mM potassium phosphate/150mM NaCl buffer using a 100 to 300 kDa NMWL membrane filter. This sterile bulk is stored at 2°C to 8°C and adsorption
20 performed within three months. The fimbrial agglutinin preparation contained fimbrial Agg 2 and fimbrial Agg 3 in a weight ratio of about 1.5 to about 2:1 and was found to be substantially free from Agg 1.

Example 3:

25 This Example describes the toxoiding of the purified Bordetella pertussis antigens, PT and FHA.

PT, prepared in pure form as described in Example 2, was toxoided by adjusting the glutaraldehyde concentration in the PT solution to 0.5% \pm 0.1% and
30 incubating at 37°C \pm 3°C for 4 hours. The reaction was stopped by adding L-aspartate to 0.21 \pm 0.02M. The mixture was then held at room temperature for 1 \pm 0.1 hours and then at 2°C to 8°C for 1 to 7 days.

The resulting mixture was diafiltered against 10mM
35 potassium phosphate/0.15M NaCl/5% glycerol buffer on a 30 kDa NMWL membrane filter and then sterilized by passage

through a $\leq 0.22 \mu\text{m}$ membrane filter. This sterile bulk was stored at 2°C to 8°C and adsorption performed within three months.

5 The FHA fraction, prepared in pure form as described in Example 2, was toxoided by adjusting the L-lysine and formaldehyde concentration to $47 \pm 5\text{mM}$ and $0.24 \pm 0.05\%$ respectively and incubating at 35°C to 38°C for 6 weeks. The mixture was then diafiltered against 10mM potassium phosphate/ 0.5M NaCl using a 30 kDa NMWL membrane filter
10 and sterilized by passage through a membrane filter. This sterile bulk was stored a 2°C to 8°C and adsorption performed within three months.

Example 4:

15 This Example describes the adsorption of the purified Bordetella pertussis antigens.

For the individual adsorption of PT, FHA, Agg and 69 kDa onto aluminum phosphate (alum), a stock solution of aluminum phosphate was prepared to a concentration of $18.75 \pm 1 \text{ mg/ml}$. A suitable vessel was prepared and any
20 one of the antigens aseptically dispensed into the vessel. 2-phenoxyethanol was aseptically added to yield a final concentration of $0.6\% \pm 0.1\% \text{ v/v}$ and stirred until homogeneous. The appropriate volume of aluminum phosphate was aseptically added into the vessel. An
25 appropriate volume of sterile distilled water was added to bring the final concentration to 3 mg aluminum phosphate/ml. Containers were sealed and labelled and allowed to stir at room temperature for 4 days. The vessel was then stored awaiting final formulation.

30 Example 5:

This Example describes the formulation of a component pertussis vaccine combined with diphtheria and tetanus toxoids.

35 The B. pertussis antigens prepared as described in the preceding Examples were formulated with diphtheria

and tetanus toxoids to provide several component pertussis (CP) vaccines.

The pertussis components were produced from Bordetella pertussis grown in submerged culture as described in detail in Examples 1 to 4 above. After completion of growth, the culture broth and the bacterial cells were separated by centrifugation. Each antigen was purified individually. Pertussis toxin (PT) and Filamentous Haemagglutinin (FHA) were purified from the broth by sequential chromatography over perlite and hydroxylapatite. PT was detoxified with glutaraldehyde and any residual PT (approximately 1%) present in the FHA fraction was detoxified with formaldehyde. Fimbrial Agglutinogens (2+3) (AGG) were prepared from the bacterial cells. The cells were disrupted with urea and heat treated, and the fimbrial agglutinogens were purified by precipitation with polyethylene glycol and chromatography over polyethyleneimine silica. The 69 kDa protein (pertactin) component was isolated from the run through from the perlite chromatography step (Example 2) by ammonium sulphate precipitation, and purified by sequential chromatography over hydroxylapatite and Q-sepharose. All components were sterilized by filtration through a 0.22 μ m membrane filter.

Diphtheria toxoid was prepared from Corynebacterium diphtheriae grown in submerged culture by standard methods. The production of Diphtheria Toxoid is divided into five stages, namely maintenance of the working seed, growth of Corynebacterium diphtheriae, harvest of Diphtheria Toxin, detoxification of Diphtheria Toxin and concentration of Diphtheria Toxoid.

Preparation of Diphtheria Toxoid

(I) Working Seed

The strain of Corynebacterium diphtheriae was maintained as a freeze-dried seed lot. The reconstituted seed was grown on Loeffler slopes for 18 to 24 hours at

35°C ± 2°C, and then transferred to flasks of diphtheria medium. The culture was then tested for purity and Lf content. The remaining seed was used to inoculate a fermenter.

5 (II) Growth of Corynebacterium diphtheriae

The culture was incubated at 35°C ± 2°C and agitated in the fermenter. Predetermined amounts of ferrous sulphate, calcium chloride and phosphate solutions were added to the culture. The actual amounts of each
10 solution (phosphate, ferrous sulphate, calcium chloride) were determined experimentally for each lot of medium. The levels chosen are those which gave the highest Lf content. At the end of the growth cycle (30 to 50 hours), the cultures were sampled for purity, and Lf
15 content.

The pH was adjusted with sodium bicarbonate, and the culture inactivated with 0.4% toluene for 1 hour at a maintained temperature of 35°C ± 2°C. A sterility test was then performed to confirm the absence of live C.
20 diphtheriae.

(III) Harvest of Diphtheria Toxin

The toluene treated cultures from one or several fermenters were pooled into a large tank. Approximately 0.12% sodium bicarbonate, 0.25% charcoal, and 23%
25 ammonium sulphate were added, and the pH was tested.

The mixture was stirred for about 30 minutes. Diatomaceous earth was added and the mixture pumped into a depth filter. The filtrate was recirculated until clear, then collected, and sampled for Lf content
30 testing. Additional ammonium sulphate was added to the filtrate to give a concentration of 40%. Diatomaceous earth was also added. This mixture was held for 3 to 4 days at 2°C to 8°C to allow the precipitate to settle. Precipitated toxin was collected and dissolved in 0.9%
35 saline. The diatomaceous earth was removed by filtration and the toxin dialysed against 0.9% saline, to remove the

ammonium sulphate. Dialysed toxin was pooled and sampled for Lf content and purity testing.

(IV) Detoxification of Diphtheria Toxin

Detoxification takes place immediately following dialysis. For detoxification, the toxin was diluted so that the final solution contained:

- a) diphtheria toxin at $1000 \pm 10\%$ Lf/ml.
- b) 0.5% sodium bicarbonate
- c) 0.5% formalin
- 10 d) 0.9% w/v L-lysine monohydrochloride

The solution was brought up to volume with saline and the pH adjusted to 7.6 ± 0.1 .

Toxoid was filtered through cellulose diatomaceous earth filter pads and/or a membrane prefilter and 0.2 μm membrane filter into the collection vessel and incubated for 5 to 7 weeks at 34°C . A sample was withdrawn for toxicity testing.

(V) Concentration of Purified Toxoid

The toxoids were pooled, then concentrated by ultrafiltration, and collected into a suitable container. Samples were taken for Lf content and purity testing. The preservative (2-phenoxyethanol) was added to give a final concentration of 0.375 % and the pH adjusted to 6.6 to 7.6.

The toxoid was sterilized by filtration through a prefilter and a 0.2 μm membrane filter (or equivalent) and collected. The sterile toxoid was then sampled for irreversibility of toxoid Lf content, preservative content, purity (nitrogen content), sterility and toxicity testing. The sterile concentrated toxoid was stored at 2°C to 8°C until final formulation.

Preparation of Tetanus Toxoid

Tetanus toxoid (T) was prepared from Clostridium tetani grown in submerged culture.

The production of Tetanus Toxoid can be divided into five stages, namely maintenance of the working seed,

growth of Clostridium tetani, harvest of Tetanus Toxin, detoxification of Tetanus Toxin and purification of Tetanus Toxoid.

(I) Working Seed

5 The strain of Clostridium tetani used in the production of tetanus toxin for the conversion to tetanus toxoid was maintained in the lyophilized form in a seed-lot. The seed was inoculated into thioglycollate medium and allowed to grow for approximately 24 hours at $35^{\circ}\text{C} \pm 2^{\circ}\text{C}$. A sample was taken for culture purity testing.

(II) Growth of Clostridium tetani

15 The tetanus medium was dispensed into a fermenter, heat-treated and cooled. The fermenter was then seeded and the culture allowed to grow for 4 to 9 days at $34^{\circ}\text{C} \pm 2^{\circ}\text{C}$. A sample was taken for culture purity, and Lf content testing.

(III) Harvest of Tetanus Toxin

20 The toxin was separated by filtration through cellulose diatomaceous earth pads, and the clarified toxin then filter-sterilized using membrane filters. Samples were taken for Lf content and sterility testing. The toxin was concentrated by ultrafiltration, using a pore size of 30,000 daltons.

(IV) Detoxification of Tetanus Toxin

25 The toxin was sampled for Lf content testing prior to detoxification. The concentrated toxin (475 to 525 Lf/ml) was detoxified by the addition of 0.5% w/v sodium bicarbonate, 0.3% v/v formalin and 0.9% w/v L-lysine monohydrochloride and brought up to volume with saline.

30 The pH was adjusted to 7.5 ± 0.1 and the mixture incubated at 37°C for 20 to 30 days. Samples were taken for sterility and toxicity testing.

(V) Purification of Toxoid

35 The concentrated toxoid was sterilized through pre-filters, followed by $0.2 \mu\text{m}$ membrane filters. Samples were taken for sterility and Lf content testing.

The optimum concentration of ammonium sulphate was based on a fractionation "S" curve determined from samples of the toxoid. The first concentration was added to the toxoid (diluted to 1900-2100 Lf/ml). The mixture
 5 was kept for at least 1 hour at 20°C to 25°C and the supernatant collected and the precipitate containing the high molecular weight fraction, discarded.

A second concentration of ammonium sulphate was added to the supernatant for the second fractionation to
 10 remove the low molecular weight impurities. The mixture was kept for at least 2 hours at 20°C to 25°C and then could be held at 2°C to 8°C for a maximum of three days. The precipitate, which represents the purified toxoid, was collected by centrifugation and filtration.

15 Ammonium sulphate was removed from the purified toxoid by diafiltration, using Amicon (or equivalent) ultrafiltration membranes with PBS until no more ammonium sulphate could be detected in the toxoid solution. The pH was adjusted to 6.6. to 7.6, and 2-phenoxyethanol
 20 added to give a final concentration of 0.375%. The toxoid was sterilized by membrane filtration, and samples are taken for testing (irreversibility of toxoid, Lf content, pH, preservative content, purity, sterility and toxicity).

25 One formulation of a component pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{10/5/5/3}DT. Each 0.5 ml human dose of CP_{10/5/5/3}DT was formulated to contain:

30	10 µg	Pertussis toxoid (PT)
	5 µg	Filamentous haemagglutinin (FHA)
	5 µg	Fimbrial agglutinogens 2 and 3 (FIMB)
	3 µg	69 kDa outer membrane protein
	15 Lf	Diphtheria toxoid
	5 Lf	Tetanus toxoid
35	1.5 mg	Aluminum phosphate
	0.6%	2-phenoxyethanol as preservative

Another formulation of component pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{10/5/5}DT. Each 0.5 ml human dose of CP_{10/5/5}DT was formulated to contain:

5	10 µg	Pertussis toxoid (PT)
	5 µg	Filamentous haemagglutinin (FHA)
	5 µg	Fimbrial agglutinogens 2 and 3 (FIMB)
	15 Lf	Diphtheria toxoid
	5 Lf	Tetanus toxoid
10	1.5 mg	Aluminum phosphate
	0.6%	2-phenoxyethanol as preservative

Another formulation of Component Pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{20/20/5/3}DT. Each 0.5 ml human dose of CP_{20/20/5/3}DT was formulated to contain:

15	20 µg	Pertussis toxoid (PT)
	20 µg	Filamentous haemagglutinin (FHA)
	5 µg	Fimbrial agglutinogens 2 and 3 (FIMB)
	3 µg	69 kDa outer membrane protein
20	15 Lf	Diphtheria toxoid
	5 Lf	Tetanus toxoid
	1.5 mg	Aluminum phosphate
	0.6%	2-phenoxyethanol as preservative

A further formulation of a component pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{20/10/10/6}DT. Each 0.5 ml human dose of CP_{20/10/10/6}DT was formulated to contain:

25	20 µg	Pertussis toxoid (PT)
	10 µg	Filamentous haemagglutinin (FHA)
30	10 µg	Fimbrial agglutinogens 2 and 3 (FIMB)
	6 µg	69 kDa outer membrane protein
	15 Lf	Diphtheria toxoid
	5 Lf	Tetanus toxoid
	1.5 mg	Aluminum phosphate
35	0.6%	2-phenoxyethanol as preservative

Example 6:

This Example describes the clinical assessment of Component Acellular Pertussis vaccines, produced in accordance with the invention.

5 (a) Studies in Adults

Studies in adults and children aged 16 to 20 months indicated the multi-component vaccines containing fimbrial agglutinogens to be safe and immunogenic (Table 2).

10 A Phase I clinical study was performed in 17 and 18 month old children in Calgary, Alberta with the five Component Pertussis vaccine (CP_{10/5/5/3}DT) and the adverse reaction reported. Thirty-three children received the vaccine and additionally 35 received the same vaccine
15 without the 69 kDa protein component.

Local reactions were rare. Systemic adverse reactions, primarily consisting of irritability were present in approximately half of study participants, regardless of which vaccine was given. Significant
20 antibody rises were measured for anti-PT, anti-FHA, anti-fimbrial agglutinogens and anti-69kDa IgG antibodies by enzyme immunoassay and anti-PT antibodies in the CHO cell neutralization test. No differences in antibody response were detected in children who received the four
25 component (CP_{10/5/5}DT) or five component (CP_{10/5/5/3}DT) except in the anti-69kDa antibody. Children who received the five component vaccine containing the 69 kDa protein had a significantly higher post-immunization anti-69 kDa antibody level.

30 A dose-response study was undertaken with the 4 component vaccine in Winnipeg, Manitoba, Canada. Two component vaccine formulations were used: CP_{10/5/5/3}DT and CP_{20/10/10/6}DT. A whole-cell DPT vaccine was also included as a control.

35 This study was a double-blind study in 91, 17 to 18 month old infants at the time of their booster pertussis

dose. Both CP_{10/5/5/3}DT and CP_{20/10/10/6}DT were well tolerated by these children. No differences were demonstrated in the number of children who had any local reaction, or systemic reactions after either of the component
 5 vaccines. In contrast, significantly more children who received the whole-cell vaccine had local and systemic reactions than those who received the CP_{20/10/10/6}DT component vaccines.

Studies in Infants:

10 Phase II:

A study was conducted using the CP_{10/5/5/3}DT vaccine in Calgary, Alberta and British Columbia, Canada. In this study, 432 infants received the component pertussis vaccine or the whole-cell control vaccine DPT at 2, 4 and
 15 6 months of age. The CP_{10/5/5/3}DT vaccine was well tolerated by these infants. Local reactions were less common with the component vaccine than the whole cell vaccine after each dose.

A significant antibody response to all antigens was
 20 demonstrated after vaccination with the component pertussis vaccine. Recipients of the whole-cell vaccine had a vigorous antibody response to fimbrial agglutinogens, D and T. At seven months, 82% to 89% of component vaccine recipients and 92% of whole cell
 25 vaccine recipients had a four-fold increase or greater rise in antibody titer to fimbrial agglutinogens. In contrast, antibody response to FHA was 75% to 78% in component vaccines compared to 31% of whole-cell recipients. A four-fold increase in anti-69 kDa antibody
 30 was seen in 90% to 93% of component vaccines and 75% of whole-cell recipients. A four-fold rise in antibody against PT by enzyme immunoassay was seen in 40% to 49% of component vaccines and 32% of whole-cell vaccines; a four-fold rise in PT antibody by CHO neutralization was
 35 found in 55% to 69% of component and 6% of whole-cell vaccines. (Table 2).

Phase IIB:

The CP_{20/20/5/3}DT and CP_{10/10/5/3}DT vaccines were assessed in a randomized blinded study against a D₁₅PT control with a lower diphtheria content of 15 Lf compared to a 25 Lf formulation of 100 infants at 2, 4 and 6 months of age. No differences in rates of adverse reactions were detected between the two components formulations; both were significantly less reactogenic than the whole-cell control. Higher antibody titers against PT by enzyme immunoassay and CHO neutralization and FHA were achieved in recipients of the CP_{20/20/5/3}DT vaccine with increased antigen content. At 7 months, the anti-FHA geometric mean titer was 95.0 in CP_{20/20/5/3}DT recipients, 45.2 in CP_{10/5/5/3}DT recipients were only 8.9 in D₁₅PT recipients. Anti-PT titers were 133.3, 58.4 and 10.4 by immunoassay and 82.4, 32.7 and 4.0 by CHO neutralization respectively (Table 2).

This study demonstrated that the Component Pertussis vaccine combined with diphtheria and tetanus toxoids adsorbed, with increased antigen content, was safe and immunogenic in infants and that the increased antigen content augmented the immune response to the prepared antigens (PT and FHA) without an increase in reactogenicity.

NIAID, PHASE II, U.S. Comparative Trial:

A phase II study was performed in the United States under the auspices of the National Institute of Allergy and Infectious Diseases (NIAID) as a prelude to a large scale efficacy trial of acellular pertussis vaccines. One component pertussis vaccine of the invention in combination with diphtheria and tetanus toxoids adsorbed (CP_{10/5/5/3}DT) was included in that trial along with 12 other acellular vaccines and 2 whole-cell vaccines. Safety results were reported on 137 children immunized at 2, 4 and 6 months of age with the CP_{10/5/5/3}DT component vaccine.

As seen in previous studies, the component vaccine was found to be safe, of low reactogenicity and to be well tolerated by vaccines.

At 7 months, anti-PT antibody, anti-FHA antibody, anti-69kDa antibody and anti-fimbrial agglutinogens antibody were all higher than or equivalent to levels achieved after the whole-cell vaccines (ref 71 and Table 2). A double blind study was performed in which children were randomly allocated to receive either the CP_{20/20/5/3}DT or the CP_{10/5/5/3}DT vaccine formulation. A total of 2050 infants were enrolled in the United States and Canada; 1961 infants completed the study. Both vaccine formulations were safe, of low reactogenicity and immunogenic in these infants. Immunogenicity was assessed in a subgroup of 292. An antibody rise was elicited to all antigens contained in the vaccine by both vaccine formulations. The CP_{20/20/5/3}DT formulation induced higher antibody titers against FHA but not PT. The CP_{10/5/5/3}DT formulation elicited higher titers against fimbriae and higher agglutinin titers.

A further safety and immunogenicity study was conducted in France. The study design was similar to the North American study, described above, except that vaccines were administered at 2, 3 and 4 months of age. Local and systemic reactions were generally minor. Overall the vaccine was well accepted by the French study participants using this administration regime.

Placebo-controlled efficacy trial of two acellular pertussis vaccines and of a whole-cell vaccine in 10,000 infants

Following the results of the NIAID Phase II U.S. comparative trial, a two-component and a five-component acellular vaccine were selected for a multi-centre, controlled, double-randomized placebo-controlled efficacy trial. The clinical trial was performed in Sweden, where there is a high incidence of pertussis. The two-component vaccine contained glyceraldehyde and formalin

inactivated PT (25 μ g), formalin treated FHA (25 μ g) and diphtheria toxoid 17 Lf and tetanus toxoid 10 Lf. The five-component pertussis vaccine was CP_{10/5/5/3}DT. For the trial, ten thousand infants, representing approximately
5 one-half the infants of this age group in Sweden, were recruited in 14 geographically defined study sites by use of birth registry.

Children born in January and February 1992 were randomized into a 3-armed trial. After parental consent,
10 two-thirds of the infants received one out of the two diphtheria-tetanus-acellular pertussis preparations at two, four and six months of age. The control group received DT only. In May 1992, a U.S. Licensed commercially-available whole-cell DTP vaccine was
15 introduced and children born in March through December 1992 were randomized into a 4-armed trial. After parental consent, three-quarters of the infants received one out of three DTP preparations at two, four and six months of age. The control group received DT only.

20 Each vaccine was administered to about 2,500 children. Vaccines were administered in three doses. The first dose was given at 2 months of age and not later than 3 months of age. Subsequent doses were given with 8 week intervals. Vaccines were given by intramuscular
25 injection.

The children and their households were followed for 30 months. If pertussis was suspected, clinical data was collected, and laboratory verification sought by nasal aspirates for bacteriological culture and polymerase
30 chain reaction (PCR) diagnosis. Acute and convalescent blood samples were collected for serological diagnosis.

Prior to this study, the extent of pertactin afforded by component pertussis vaccines of the present invention in an at-risk human population (particularly
35 neonates) was unknown. In particular, the contribution of the various Bordetella components and their presence

in pertussis vaccines in selected relative amounts to efficacy of the vaccines was not known.

The main aim of the trial was to estimate the ability of acellular pertussis vaccines and whole-cell vaccine to protect against typical pertussis as compared to placebo.

A secondary end-point was to explore vaccine efficacy against confirmed pertussis infection of varying severity.

Vaccine efficacy is defined as the per cent reduction in the probability of contracting pertussis among vaccine recipients relative to unvaccinated children.

The relative risk of pertussis in two vaccine groups is expressed as the ratio of the disease probability in the two groups.

The probability of contracting pertussis, also called the attack rate, can be estimated in different ways. In the calculations of the sample size, the probability of contracting pertussis in a given study group is estimated by the quotient between the number of children with pertussis and the children remaining in the study group at the termination of study follow-up.

The efficacy of the component vaccine CP_{10/5/5/3}DT in this trial in preventing typical pertussis is shown in Table 4 and was about 85%. In the same trial, a two-component pertussis acellular vaccine containing only PT and FHA was about 58% efficacious and a whole-cell vaccine was about 48% efficacious. The CP_{10/5/5/3}DT was also effective in preventing mild pertussis at an estimated efficacy of about 77%.

SUMMARY OF DISCLOSURE

In summary of this disclosure, the present invention provides novel preparations of fimbrial agglutinogens of Bordetella pertussis and methods for their production. The fimbrial agglutinogens can be formulated with other

Bordetella and non-Bordetella antigens to produce a number of multi-component pertussis vaccines. Such vaccines are safe, non-reactogenic, immunogenic and protective in humans. Modifications are possible within
5 the scope of this invention.

Table 1. Acellular Pertussis Vaccines

Vaccine	PT	Toxoiding Agent	FHA	P.69	AGG2	AGG3	Reference
AMVC	+	H ₂ O ₂ ^a	-	-	-	-	62
Mass PHL ^b	+	TNM ^c	-	-	-	-	63
Institut Mérieux	+	GI ^d	+	-	-	-	64
Smith-Kline	+	FI ^e /GI	+	-	-	-	32
	+	FI/GI	+	+	-	-	32
CAMR ^f	+	FI	+	-	+	+	65
Lederle/Takeda	+	FI	+	+	+	-	66
Connaught	+	GI	+	-	+	+	32
	+	GI	+	+	+	+	67

^a Hydrogen peroxide inactivated. ^b Massachusetts Public Health Laboratories. ^c TNM, tetranitromethane-inactivated.

^d GI, glutaraldehyde-inactivated. ^e FI, formalin-inactivated. ^f Centre for Applied Microbiology and Research.

Table 2.

IgG antibody responses to pertussis antigen and diphtheria and tetanus toxoids in adults and young children after immunization with placebo or acellular pertussis (AP), diphtheria-tetanus-pertussis (DTP), or multicomponent acellular DTP (ADTP) toxoids.

	Adults				Children			
	Before immunization		Postimmunization day 28		Before immunization		After immunization	
	Placebo	AP CP _{10/10/5/3}	Placebo	AP CP _{10/10/5/3}	DTP	ADTP CP _{10/10/5/3} DT	DTP	ADTP CP _{10/10/5/3} DT
Pertussis toxoid	16.45 (9.46-28.62)	22.78 (12.11-42.86)	16.56 (9.08-30.22)	415.87 (243.91-709.09)	43.71 (14.29-133.88)	15.45 (8.50-28.10)	221.32 (99.83-490.67)	306.55 (155.84-603.03)
Filamentous hemagglutinin	15.24 (10.28-22.60)	23.59 (15.59-35.69)	13.36 (7.71-23.16)	317.37 (243.05-141.41)	2.93 (1.81-4.73)	3.86 (3.03-4.93)	30.06 (11.82-76.46)	29.86 (16.51-53.99)
Agglutinogens	21.26 (12.14-37.23)	28.64 (12.20-67.21)	27.0 (15.37-47.78)	2048.00 (1025.62-4089.55)	26.72 (16.94-42.15)	29.24 (13.63-62.75)	315.2 (127.4-779.9)	1243.3 (594.8-2603.5)
Pertactin	7.89 (4.00-15.56)	11.47 (6.41-20.55)	7.46 (3.51-15.87)	855.13 (396.41-1844.67)	6.54 (2.79-15.33)	9.45 (5.50-16.23)	60.13 (24.59-147.04)	116.16 (57.87-233.19)
CHO cell neutralizing assay	12.30 (6.97-21.68)	21.11 (10.35-43.06)	10.78 (5.54-20.97)	604.67 (403.82-405.41)	27.47 (7.36-102.62)	9.71 (4.71-20.03)	270.60 (24.6-1100.8)	342.51 (146.6-800.2)
Diphtheria toxoid	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	8.75 (6.52-23.92)	9.65 (5.62-16.57)
Tetanus toxoid	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	4.11 (3.20-5.28)	6.32 (5.31-7.53)
No. studied	16	15	16	15	10	25	12	25

Data are expressed as geometric mean with 95% confidence intervals. For pertussis toxoid, filamentous hemagglutinin, agglutinogens, pertactin, and diphtheria and tetanus toxoids, antibody titers expressed as ELISA units/nL. For CHO cell neutralizing assay, values reflect reciprocal of highest dilution demonstrating 80% neutralization.

TABLE 3. Serologic Results of Acellular Pertussis Vaccines In Infants
(2, 4 and 6 Months Old)

Clinical Trial	Geometric Mean Titres										
	Product	Study	Number of Participants	PT	FHA	69 kDa	Fimbrial agglutinogens	CHO Cell Neutralization	Agglutination	Tet	Dip
1	CP _{100/5/3} DT	U.S. NIAID Multicentre Comparative Study (Cycle I)	108	38	37	3	229	160	85	7.8	0.8
	CP _{100/5/3/3} DT		113	36	36	113	241	150	73	5.0	0.4
	Whole Cell (Mass.)		95	20	51	101	70	80	42	-	-
	Whole Cell (Lederle)		312	67	3	64	193	270	84	-	-
2	CP _{100/5/3} DT	Phase II Canada	315	87.1	50.2	29.9	239.8	29.6	-	1.5	0.3
	Whole Cell (CLL)		101	20	4.7	6.4	603.2	2.6	-	1.2	0.4
3	CP _{100/5/3} DT	Phase IIB Canada	32	58.4	45.2	40.6	111.4	32.7	-	1.0	0.14
	CP _{200/20/3/3} DT		33	133.3	95.0	37.1	203.8	82.4	-	1.1	0.21
	Whole Cell (CLL)		30	10.4	8.9	6.8	393.9	4.0	-	1.8	0.31
4	CP _{100/5/3} DT	Phase IIC Canada	42	105.1	82.5	71.1	358.6	66.9	307.0	2.0	0.33
	CP _{200/20/3/3} DT		250	101.6	163.9	87.6	220.6	68.7	219.2	1.8	0.38
5	CP _{200/20/3/3} DT	Montreal Feasibility Study	58	212.7	83.4	106.3	601.9	109.6	-	1.9	0.53
	Whole Cell (CLL)		58	101.4	11.7	16.8	906.9	6.0	-	1.1	0.27
6	CP _{100/5/3} DT	U.S. NIAID Comparative Study (Cycle II)	80	42	34	50	310	196	185	-	-
	CP _{200/20/3/3} DT		80	39	87	43	184	254	137	-	-
	Whole Cell (CLI)		80	2	3	9	33	54	167	-	-
	Whole Cell (Lederle)		80	18	2	16	129	137	86	-	-

CLI - Connaught Laboratories Incorporated, Swiftwater, Pennsylvania.

CLL - Connaught Laboratories Limited, Willowdale, Ontario.

Mass - Massachusetts Public Laboratories.

Lederle - Lederle Laboratories Inc.

TABLE 4 - Efficacy of Acellular Pertussis Vaccines

	<u>Vaccine</u>	<u>Efficacy %</u>	
		<u>A</u>	<u>B</u>
5	CP _{10/5/5/3} DT	84.7 (80.3→88.5) ¹	77
	PT ₂₅ .FHA ₂₅ DT	58 (49.8→64.8) ¹	
	DPT ²	47.9 (37.1→56.9) ¹	
10	A: case definition:	21 day spasmodic cough and culture positive	
	B: case definition:	mild pertussis cough of at least one day	
	Note 1: confidence limits		
15	Note 2: whole cell pertussis vaccine		

REFERENCES

1. Muller, A.S. Leeuwenburg, J. and Pratt, D.S. (1986) Pertussis: epidemiology and control. Bull WHO 64: 321-331.
2. Fine, P.E.M. and Clarkson, J.A. (1984). Distribution of immunity to pertussis in the population of England and Wales. J. Hyg. 92:21-26.
3. Mortimer, E.A. Jr. (1990). Pertussis and its prevention: a family affair. J. Infect. Dis. 161: 473-479.
4. Addiss, D.G., Davis, I.P., Meade, B.D., Burstyn, D.G. Meissner, M., Zastrow, J.A., Berg, J.L., Drinka, P., and Phillips, R. (1991). A pertussis outbreak in a Wisconsin nursing home. J. Infect. Dis. 164: 704-710.
5. Halperin, S.A. and Marrie, T.J. (1991a). Pertussis encephalopathy in an adult: case report and review. Rev. Infect. Dis. 13: 1043-1047.
6. Onorato, I.M., Wassilak, S.G. and Meade, B. (1992). Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA 267: 2745-2749.
7. Miller, D.L., Ross, E.M., Alderslade, R., Bellman, M.H., and Brawson, N.S.B. (1981). Pertussis immunization and serious acute neurological illness in children. Brit Med. J. 282: 1595-1599.
8. Tamura, M., Nogimori, K., Murai, S., Yajima, M., Ito, K., Katada, T., Ui, M., and Ishii, S. (1982). Subunit structure of islet-activating protein. pertussis toxin, in conformity with the A-B model. Biochemistry 21: 5516-5522.
9. Tuomanen, E. and Weiss, A. (1985). Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory epithelial cells. J. Infect. Dis. 152:118-125.
10. Friedman, R-L., Nordensson, K., Wilson, L., Akporiaye, E.T., and Yocum D.E. (1992). Uptake and intracellular survival of Bordetella pertussis in human macrophages. Infect. Immun. 60: 4578-4585
11. Pittman, M (1979). Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev. Infect. Dis., 1: 401-402

12. Granstrom, M. and Granstrom G. (1993). Serological correlates in whooping cough. Vaccine 11:445-448.
13. Gearing, A.J.H., Bird, C.R., Redhead, K., and Thomas, M. (1989). Human cellular immune responses to Bordetella pertussis infection. FEMS Microbial. Immunol. 47: 205-212.
14. Thomas, M.G., Redhead, K., and Lambert, H.P. (1989a). Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination. J. Infect. Dis. 159: 211-218.
15. Thomas, M.G., Ashworth, L.A.E., Miller, E., and Lambert, H.P. (1989b). Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous haemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine. J. Infect. Dis. 160: 838-845.
16. Tomoda, T., Ogura, H., and Kurashige, T. (1991). Immune responses to Bordetella pertussis infection and vaccination. J. Infect. Dis. 163: 559-563.
17. Petersen, J.W., Ibsen, P.H., Haslov, K., Capiiau, C., and Heron, I. (1992a). Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from trachobroncheal lymph nodes and spleens of mice aerosol infected with Bordetella pertussis. Infect. Immun. 60: 4563-4570
18. Englund, J.A., Reed, G.F., Edwards, K.M., Decker, D., Pichichero, M.E., Ronnels, M.B., Steinhoff, M.C., Anderson, E.L., Meade, B.D., Deloria, M.A., and the NIAID Acellular Pertussis Vaccine Group. (1992b). Effect of transplacental antibody and development of pertussis toxin (PT) and filamentous haemagglutinin (FHA) antibody after acellular (AC) and whole cell (WC) pertussis vaccines in infants. Pediat. Res. 31:91A.
19. Oda, M., Cowell, J.L., Burstyn, D.G., Thaib, S., and Manclark, C.R. (1985). Antibodies to Bordetella pertussis in human colostrum and their protective activity against aerosol infection of mice. Infect. Immun. 47:441-445.
20. Petersen, J.W., P.H. Bentzon, M.W., Capiiau, C., and Heron, I. (1991). The cell mediated and humoral immune response to vaccination with acellular and whole cell pertussis vaccine in adult humans. FEMS Microbiol Lett. 76: 279-288.

21. Oda, M., Cowell, J.L., Burstyn, D.G., and Manclark, C.R. (1984). Protective activities of the filamentous haemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J. Infect. Dis. 150: 823-833.
22. Sato, H., Ito, A., Chiba, J. and Sato, Y. (1984b). Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect. Immun. 46: 422-428.
23. Sato, H. and Sato, Y. (1990). Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect. Immun. 58: 3369-3374.
24. Weiss, A.A. and Hewlett, E.L. (1986). Virulence factors of Bordetella pertussis. Ann. Rev. Microbiol 40: 661-668.
25. Munoz, J.J. (1988). Action of pertussigen (pertussis toxin) on the host immune system. In: Pathogenesis and Immunity in Pertussis. A.C. Wardlaw and R. Parton, eds., John Wiley & Sons Ltd., Toronto. pp. 211-229.
26. Watkins, P.A., Burns, D.L., Kanaho, Y., Liu, T-Y., Hewlett E.L., and Moss, J. (1985). ADP-ribosylation of transducin by pertussis toxin. J. Biol. Chem. 260: 13478-13482.
27. Burns, D.L., Kenimer, J.G., and Manclark, C.R. (1987). Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology. Infect. Immun., 55: 24-28.
28. Munoz, J.J., Arai, H., and Cole, R.L. (1981). Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinins from Bordetella pertussis. Infect. Immun. 32: 243-250.
29. Relman, D.A., Domenighini, M., Tuomanen, E., Rappuoli, R., and Falkow, S. (1989). Filamentous haemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence. Proc. Natl. Acad. Sci. USA 86: 2637-2641.
30. Di Tommaso, A., Domenighini, M., Bugnoli, M., Tagliabuc, A., Rappuoli, R., and De Magistris, M.T. (1991). Identification of subregions of Bordetella pertussis filamentous haemagglutinin that stimulate human T-cell responses. Infect. Immun. 59: 3313-3315.

31. Tomoda, T., Ogura, H., and Kurashige, T. (1992). The longevity of the immune response to filamentous haemagglutinin and pertussis toxin in patients with pertussis in a semiclosed community. J. Infect. Dis. 166: 908-910.
32. Edwards, K.M., Meade, B.D., Decker, M.D., Reed, G.F., Rennels, M.B., Steinhoff, M.C., Anderson, E.L., Englund, J.A., Pichichero, M.E., Deloria, M.A., Deforest, A., and the NIAID Acellular Pertussis Vaccine Study Group (1992). Comparison of thirteen acellular pertussis vaccines: serological response. Pediatr. Res. 31:91A.
33. Kimura, A., Mountzoutos, K.T., Relman, D.A., Falkow, S., and Cowell, J.L. (1990a). Bordetella pertussis filamentous haemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Infect. Immun. 58:7-16.
34. Shahin, R.D., Amsbaugh, D.F., and Leef, M.F. (1992). Mucosal immunization with filamentous haemagglutinin protects against Bordetella pertussis respiratory infection. Infect. Immun. 60: 1482-1488.
35. Montaraz, J.A., Novotny, P., and Ivanyi, J. (1985). Identification of a 68-kilodalton protective protein antigen from Bordetella bronchiseptica. Infect. Immun. 161: 581-582.
36. Leininger, E., Roberts, M., Kenimer, J.G., Charles, I.G., Fairweather, M., Novotny, P., and Brennan, M.J (1991). Pertactin, and Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc. Natl. Acad. Sci. USA 88: 345-349.
37. De Magistris, T., Romano, M., Nuti, S., Rappuoli, R. and Tagliabue, A. (1988). Dissecting human T responses against Bordetella species J. Exp. Med. 168: 1351-1362.
38. Seddon, P.C., Novotny, P., Hall, C.A., and Smith, C.S. (1990). Systemic and mucosal antibody response to Bordetella pertussis antigens in children with whooping cough. Serodiagnosis Immunother. Inf. Dis. 3: 337-343.
39. Podda, A., Nencioni, L., Marsili, I., Peppoloni, S., Volpini, G., Donati, D., Di Tommaso, A., De Magistris, M.T., and Rappuoli, R. (1991). Phase I clinical trial of an acellular pertussis vaccine

composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. Vaccine 9: 741-745.

40. Roberts, M., Tite, J.P., Fairweather, N.F., Dougan, G. and Charles, I.G. (1992). Recombinant P.69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection. Vaccine 10: 43-48.
41. Novotny, P., Chubb, A.P., Cownley, K., and Charles, I.G. (1991). Biological and protective properties of the 69kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular vaccine. J. Infect. Dis. 164: 114-122.
42. Shahin, R. D., Brennan, M.J., Li. Z.M., Meade, B.D., and Manclark, C.R. (1990b). Characterization of the protective capacity and immunogenicity of the 69kD outer membrane protein of Bordetella pertussis. J. Exp. Med. 171: 63-73.
43. Robinson, A., Irons, L.I., and Ashworth, L.A.E. (1985a). Pertussis vaccine: present status and future prospects. Vaccine 3: 11-22.
44. Robinson, A., Ashworth, L.A.E. Baskerville, A., and Irons, L.I. (1985b). Protection against intranasal infection of mice with Bordetella pertussis. Develop. Biol. Stand. 61: 165-172
45. Robinson, A., Gorringe, A.R., Funnell, S.G.P., and Fernandez, M. (1989b). Serospecific protection of mice against infection with Bordetella pertussis. Vaccine 7: 321-324.
46. Sato, Y., Kimura, M., and Fukumi, H. (1984a). Development of a pertussis component vaccine in Japan. Lancet i: 122-126.
47. Kimura, M. (1991). Japanese clinical experiences with acellular pertussis vaccines. Develop. Biol. Standard. 73: 5-9.
48. Ad Hoc Group for the Study of Pertussis Vaccines (1988). Placebo-controlled trial of two acellular vaccines in Sweden-protective efficacy and adverse effects. Lancet i: 955-960.
49. Olin, P., Storsaeter, J., and Romanus, V. (1989). The efficacy of acellular pertussis vaccine. JAMA 261:560.
50. Storsaeter, J., Hallander, H., Farrington, C.P., Olin, P., Moliby, R., and Miller, E. (1990).

Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 8: 457-462.

51. Storsaeter, J., and Olin, P. (1992). Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine: 10: 142-144.
52. Tan, L.U.T., Fahim R.E.F., Jackson, G., Phillips, K., Wah, P., Alkema, D., Zobrist, G., Herbert, A., Boux, L., Chong, P., Harjee, N., Klein, M., and Vose, J. (1991). A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous haemagglutinin. Molec. Immunol. 28: 251-255.
53. Sekura, R.D., Zhang, Y., Roberson, R., Acton, B., Trollfors, B., Tolson, N., Siloach, J., Bryla, D., Muir-Nash, J., Koeller, D., Schneerson, R., and Robbins, J.B. (1988). Clinical, metabolic, and antibody responses of adult volunteers to an investigation vaccine composed of pertussis toxin inactivated by hydrogen peroxide. J. Pediatr. 113: 807-813.
54. Winberry, L., Walker, R., Cohen, N., Todd, C., Sentissi, A., and Siber, G. (1988), Evaluation of a new method for inactivating pertussis toxin with tetranitromethane. International Workshop on Bordetella pertussis, Rocky Mountain Laboratories, Hamilton, Montana.
55. Sekura, R.D. et al. (1993), J.Biol. Chem. 258: 14647-14651.
56. Irons, L.I. et al. (1979), Biochem. Biophys. Acta 580: 175-185.
57. Munoz, J.J. et al. (1981). Infect. Immun. 33: 820-826.
58. Cowell, J.L. et al. (1980), Seminar on Infectious Diseases 4: 371-379.
59. Selmer, J.C. (1984) Acta Path. Microbial. Immunol. Scand. Sect. C, 92: 279-284.
60. Lockhoff, O. (1991) Glycolipids as Immunomodulators: Synthesis and Properties, Chem. Int. Ed. Engl. 30: 1611-1620.
61. Nixon-George, A., Moran, T., Dionne, G., Penney, C.L., Lafleur, D., Bona, C.A. (1990) The adjuvant

effect of stearyl tyrosine on a recombinant subunit hepatitis B surface antigen. J. Immunol. 144: 4798-4802.

62. Siber, G.R., Thakrar, N., Yancey, B.A., Herzog, L., Todd, C., Cohen, N., Sekura, R.D., Lowe, C.U. (1991). Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. Vaccine 9: 735-740.
63. Siber, G., Winberry, L., Todd, C., Samore, M., Sentissi, A., and Cohen, N. (1988). Safety and immunogenicity in adults of pertussis toxoid inactivated with tetronitromethane. In: International Workshop on Bordetella pertussis, Rocky Mountain Laboratories, Hamilton, Montana.
64. Edwards, K.M., Bradley, R.B., Decker, M.D., Palmer, P.S., Van Savage, J., Taylor, J.C., Dupont, W.D., Hager, C.C., and Wright, P.F. (1989). Evaluation of a new highly purified pertussis vaccine in infants and children. J. Infect. Dis. 160: 832-837.
65. Rutter, D.A., Ashworth, L.A.E., Day, A., Funnell, S., Lovell, F., and Robinson, A. (1988). Trial of new acellular pertussis vaccine in healthy adult volunteers. Vaccine 6: 29-32.
66. Blumberg, D.A., Mink, C.A.M, Cherry, J.D., Johnson, C., Garber, R., Plotkin, S.A., Watson, B., Ballanco, G.A., Daum R.S., Sullivan B., Townsend, T.R. Brayton, J., Gooch, W.M., Nelson, D.B., Congeni, B.L., Prober, C.G., Hackell, J.G., Dekker, C.L., Christenson, P.D., and the APDT Vaccine Study Group (1991). Comparison of acellular and whole cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. J. Pediatr. 119: 194-204.
67. Englund, J.A., Glezen, W.P. and Barreto, L. (1992a). Controlled study of a new five-component acellular pertussis vaccine in adults in young children. J. Inf. Dis. 166: 1436-1441.
68. Zealey, G., Loosmore, S., Yacoob, R., Klein, M., Vaccine Research, Vol. 1, pp. 413-427.